Slingshot members are tracking this event:
Agios (AGIO) Announces Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Mar 30, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 1/2 Study, Ag-221, Ag-120, Vidaza, Acute Myeloid Leukemia, Drug Combinations